Drugs / Alobresib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02392611 | Mar 2015 → Oct 2017 | lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02983604 | Jan 2017 → Jul 2018 | estrogen-receptor positive breast cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT02607228 | Dec 2015 → Oct 2017 | castration-resistant prostate carcinoma | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alobresib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02607228 ↗ |
| Known as | GS-5829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02983604 ↗ |
| Modality | Small molecule | — CHEMBL3982690 ↗ |
| Route | Oral | “Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle” NCT02392611 ↗ |